The move will be a boost for Donald Trump's incoming administration. But it will be seen as a setback for the Labour Government.

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

Q3 2024 Earnings Call Transcript November 15, 2024 Operator: Hello, and welcome to the AIM ImmunoTech Third Quarter 2024 ...